- Home
- KPLT vs RLYB Comparison
KPLT vs RLYB Comparison
Compare KPLT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- RLYB
- Stock Information
- Founded
- KPLT 2012
- RLYB 2018
- Country
- KPLT United States
- RLYB United States
- Employees
- KPLT N/A
- RLYB N/A
- Industry
- KPLT Diversified Commercial Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- RLYB Health Care
- Exchange
- KPLT Nasdaq
- RLYB Nasdaq
- Market Cap
- KPLT 33.2M
- RLYB 45.2M
- IPO Year
- KPLT N/A
- RLYB 2021
- Fundamental
- Price
- KPLT $5.92
- RLYB $0.95
- Analyst Decision
- KPLT Hold
- RLYB Buy
- Analyst Count
- KPLT 2
- RLYB 6
- Target Price
- KPLT $12.00
- RLYB $8.10
- AVG Volume (30 Days)
- KPLT 24.0K
- RLYB 106.4K
- Earning Date
- KPLT 11-06-2024
- RLYB 11-07-2024
- Dividend Yield
- KPLT N/A
- RLYB N/A
- EPS Growth
- KPLT N/A
- RLYB N/A
- EPS
- KPLT N/A
- RLYB N/A
- Revenue
- KPLT $241,789,000.00
- RLYB $598,000.00
- Revenue This Year
- KPLT $12.92
- RLYB N/A
- Revenue Next Year
- KPLT $6.30
- RLYB N/A
- P/E Ratio
- KPLT N/A
- RLYB N/A
- Revenue Growth
- KPLT 14.99
- RLYB N/A
- 52 Week Low
- KPLT $5.79
- RLYB $0.93
- 52 Week High
- KPLT $23.54
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- KPLT 36.71
- RLYB 37.53
- Support Level
- KPLT $6.09
- RLYB $0.93
- Resistance Level
- KPLT $6.91
- RLYB $1.24
- Average True Range (ATR)
- KPLT 0.48
- RLYB 0.08
- MACD
- KPLT -0.01
- RLYB -0.02
- Stochastic Oscillator
- KPLT 1.23
- RLYB 6.45
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.